News
By Chad Terhune LOS ANGELES (Reuters) -Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last ...
The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a new study into GLP-1 medicines after worrying ...
Wegovy is a GLP-1 receptor agonist that acts on key areas of the brain involved in appetite regulation and food intake ...
NICE says that in some exceptional circumstances the BMI requirements can drop down to 30, and people from some ethnic ...
Weight loss drug Wegovy, which also goes by the name Ozempic, is responsible for slimming down celebrities such as Oprah ...
Patients who took an experimental drug from Eli Lilly & Co. together with Novo Nordisk A/S’s Wegovy maintained muscle while ...
Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy in India, three months after Eli ...
A recent analysis of U.S. pharmacy claims reveals that nearly two-thirds of patients who initiated Wegovy or Zepbound in ...
GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only ...
Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback